

Gunderson Dettmer represented WindMIL Therapeutics, Inc. in latest financing round

Insights

June 18, 2018

Gunderson Dettmer served as lead counsel to WindMIL Therapeutics in its \$32.5 million Series B financing round led by Qiming Venture Partners USA with participation from Medivate Partners, Camden Partners Nexus, Domain Associates and FO XKISER.

The Gunderson Dettmer deal team was led by corporate partner Timothy Ehrlich as well as founding partner Jay Hachigian, intellectual property associate Nathan Burk and corporate and securities associates David Horne and Christopher Warren.

WindMIL Therapeutics is developing cell therapies for oncology indications.

For further details, the press release can be seen [here](#).

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Jay K. Hachigian

PARTNER

P +1 617 648 9101

David T. Horne

PARTNER

P +1 617 648 9205

Christopher K. Warren

ASSOCIATE

P +1 617 648 9180

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)